Ohad Rotenberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ohad Rotenberg has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
G. L. Goldberg
Department of Obstetrics & Gynecology, Zucker School of Medicine at Hofstra/Northwell and NorthwellHealth, Hempstead, NY, USA
2 shared publicationsD. Fridman
Department of Obstetrics and Gynecology, Duke University, Durham, NC, USA
1 shared publicationD. Y. S. Kuo
Department of Obstetrics & Gynecology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA
1 shared publicationFrancesco Paolo Giuseppe Leone
University of Milan, Clinical Sciences Institute L. Sacco, Department of Obstetrics and Gynecology, Milan, Italy
1 shared publicationGary L. Goldberg
Department of Obstetrics and Gynecology, Zucker School of Medicine at Hofstra/Northwell, Hempstead, USA
1 shared publication- Georgios Doulaveris
Department of Obstetrics and Gynecology, Division of Immunology and Infectious Diseases, Weill Cornell Medical College, New York, NY, USA
1 shared publication
Latest Publications
- Open Access
- 10 May 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (8) , 104750
Evaluating endometrial thickness for sonographic detection of neoplasia in diverse population of women
- 10 May 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (8) , 104750
Open AccessEvaluating endometrial thickness for sonographic detection of neoplasia in diverse population of women
- 3 November 2025
- Published by Wiley in Journal of Clinical Ultrasound
- Vol. 54 (3) , 731-735
Ultrasound‐Guided Endometrial Aspiration and Immunohistochemistry for Detecting Focal Metastatic Cancer
At our institution, we offer a one‐step office endometrial evaluation using the simultaneous endometrial aspiration and sonohysterography (SEAS) method. This involves pelvic ultrasound and sonohysterography, followed by ultrasound‐guided endometrial aspiration with the same catheter. The aspirated specimens are sent for histological analysis, and in difficult or inconclusive cases, immunohistochemistry (IHC) is performed to refine the diagnosis. In this manuscript, we present a case demonstrating the utility of ultrasound‐guided endometrial aspiration supported by IHC. This method should be considered in the evaluation of focal endometrial lesions and/or persistent endometrial bleeding.
- 3 November 2025
- Published by Wiley in Journal of Clinical Ultrasound
- Vol. 54 (3) , 731-735
Ultrasound‐Guided Endometrial Aspiration and Immunohistochemistry for Detecting Focal Metastatic Cancer
At our institution, we offer a one‐step office endometrial evaluation using the simultaneous endometrial aspiration and sonohysterography (SEAS) method. This involves pelvic ultrasound and sonohysterography, followed by ultrasound‐guided endometrial aspiration with the same catheter. The aspirated specimens are sent for histological analysis, and in difficult or inconclusive cases, immunohistochemistry (IHC) is performed to refine the diagnosis. In this manuscript, we present a case demonstrating the utility of ultrasound‐guided endometrial aspiration supported by IHC. This method should be considered in the evaluation of focal endometrial lesions and/or persistent endometrial bleeding.
- 2 November 2023
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 142 (6) , 1496-1499
Risk of Cancer Progression of Non–Atypical Endometrial Hyperplasia
- 2 November 2023
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 142 (6) , 1496-1499
Risk of Cancer Progression of Non–Atypical Endometrial Hyperplasia
- 23 March 2022
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 306 (3) , 579-583
The significance of “atrophic endometrium” in women with postmenopausal bleeding
We evaluated the interpretation of atrophic endometrium (AE) histology as the most common cause for postmenopausal bleeding (PMB). This theory has been accepted for several generations by gynecologists and gynecologic oncologists and has been published in past and current major gynecology textbooks. In our review of the literature, we did not find sufficient histological or clinical proof for this concept. In our view, AE is not a cause of PMB and we back this up with a review of old and current medical literature. The old studies are based on information which was obtained prior to the existence of transvaginal sonogram, sonohysterogram and hysteroscopy. Focal lesions are notorious for being missed by endometrial sampling and curettage. Recent studies show that focal endometrial lesions are a crucial cause for PMB and some of those lesions can harbor cancer. In our opinion, AE is the most common histology found because it is physiologic and a ubiquitous finding in postmenopausal women, but it is not a cause of PMB. Referring to AE as a cause of PMB may result in misdiagnosis of cancer, management delay and unnecessary intervention. To avoid misdiagnosis of cancer, transvaginal sonogram should be considered in all women with PMB and AE on pathology. If endometrial thickness is found, AE is unlikely to be the cause of the PMB and further workup is warranted to reveal the true etiology for the bleeding.
- 23 March 2022
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 306 (3) , 579-583
The significance of “atrophic endometrium” in women with postmenopausal bleeding
We evaluated the interpretation of atrophic endometrium (AE) histology as the most common cause for postmenopausal bleeding (PMB). This theory has been accepted for several generations by gynecologists and gynecologic oncologists and has been published in past and current major gynecology textbooks. In our review of the literature, we did not find sufficient histological or clinical proof for this concept. In our view, AE is not a cause of PMB and we back this up with a review of old and current medical literature. The old studies are based on information which was obtained prior to the existence of transvaginal sonogram, sonohysterogram and hysteroscopy. Focal lesions are notorious for being missed by endometrial sampling and curettage. Recent studies show that focal endometrial lesions are a crucial cause for PMB and some of those lesions can harbor cancer. In our opinion, AE is the most common histology found because it is physiologic and a ubiquitous finding in postmenopausal women, but it is not a cause of PMB. Referring to AE as a cause of PMB may result in misdiagnosis of cancer, management delay and unnecessary intervention. To avoid misdiagnosis of cancer, transvaginal sonogram should be considered in all women with PMB and AE on pathology. If endometrial thickness is found, AE is unlikely to be the cause of the PMB and further workup is warranted to reveal the true etiology for the bleeding.
- 25 October 2021
- Published by Taylor & Francis in Climacteric
- Vol. 25 (3) , 235-239
Use of aromatase inhibitors in menopausal deep endometriosis: a case report and literature review
We report and review the clinical effectiveness of aromatase inhibitors in a patient with refractory, recurrent and infiltrating endometriosis. We demonstrate excellent clinical, radiological and endoscopic responses after failure of multiple other modalities. Our case and the literature show that single-agent letrozole is capable to treat deep infiltrative endometriosis involving the rectum and the urinary tract. The use of aromatase inhibitor treatment of endometriosis in postmenopausal women makes sense, is safe and is well tolerated. Difficult cases of deep infiltrative endometriosis might require use of combined surgical and medical treatment modalities. Multidisciplinary involvement of the gynecologist, bowel surgeon, urologist and invasive radiologist might be needed. Aromatase inhibitors should be considered to be an integral part of the armamentarium in the management of women with endometriosis, especially in refractory cases that have failed conventional therapeutic modalities.
- 25 October 2021
- Published by Taylor & Francis in Climacteric
- Vol. 25 (3) , 235-239
Use of aromatase inhibitors in menopausal deep endometriosis: a case report and literature review
We report and review the clinical effectiveness of aromatase inhibitors in a patient with refractory, recurrent and infiltrating endometriosis. We demonstrate excellent clinical, radiological and endoscopic responses after failure of multiple other modalities. Our case and the literature show that single-agent letrozole is capable to treat deep infiltrative endometriosis involving the rectum and the urinary tract. The use of aromatase inhibitor treatment of endometriosis in postmenopausal women makes sense, is safe and is well tolerated. Difficult cases of deep infiltrative endometriosis might require use of combined surgical and medical treatment modalities. Multidisciplinary involvement of the gynecologist, bowel surgeon, urologist and invasive radiologist might be needed. Aromatase inhibitors should be considered to be an integral part of the armamentarium in the management of women with endometriosis, especially in refractory cases that have failed conventional therapeutic modalities.
- Open Access
- 7 August 2019
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 55 (4) , 546-551
Long‐term outcome of postmenopausal women with non‐atypical endometrial hyperplasia on endometrial sampling
Objective: To assess the long‐term outcome of postmenopausal women diagnosed with non‐atypical endometrial hyperplasia (NEH).Methods: This was a retrospective study of women aged 55 or older who underwent endometrial sampling in our academic medical center between 1997 and 2008. Women who had a current or recent (< 2 years) histological diagnosis of NEH were included in the study group and were compared with those diagnosed with atrophic endometrium (AE). Outcome data were obtained until February 2018. The main outcomes were risk of progression to endometrial carcinoma and risk of persistence, recurrence or new development of endometrial hyperplasia (EH) (‘persistent EH’). Logistic regression analysis was used to identify covariates that were independent risk factors for progression to endometrial cancer or persistent EH.Results: During the study period, 1808 women aged 55 or older underwent endometrial sampling. The median surveillance time was 10.0 years. Seventy‐two women were found to have a current or recent diagnosis of NEH and were compared with 722 women with AE. When compared to women with AE, women with NEH had significantly higher body mass index (33.9 kg/m2 vs 30.6 kg/m2; P = 0.01), greater endometrial thickness (10.00 mm vs 6.00 mm; P = 0.01) and higher rates of progression to type‐1 endometrial cancer (8.3% vs 0.8%; P = 0.0003) and persistent NEH (22.2% vs 0.7%; P < 0.0001). They also had a higher rate of progression to any type of uterine cancer or persistent EH (33.3% vs 3.5%; P < 0.0001). Women with NEH had a significantly higher rate of future surgical intervention (51.4% vs 15.8%; P < 0.0001), including future hysterectomy (34.7% vs 9.8%; P < 0.0001). On multivariable logistic regression analysis, only NEH remained a significant risk factor for progression to endometrial cancer or persistence of EH.Conclusions: Postmenopausal women with NEH are at significant risk for persistent EH and progression to endometrial cancer, at rates higher than those reported previously. Guidelines for the appropriate management of postmenopausal women with NEH are needed in order to decrease the rate of persistent disease or progression to cancer. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.
- 7 August 2019
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 55 (4) , 546-551
Open AccessLong‐term outcome of postmenopausal women with non‐atypical endometrial hyperplasia on endometrial sampling
Objective: To assess the long‐term outcome of postmenopausal women diagnosed with non‐atypical endometrial hyperplasia (NEH).Methods: This was a retrospective study of women aged 55 or older who underwent endometrial sampling in our academic medical center between 1997 and 2008. Women who had a current or recent (< 2 years) histological diagnosis of NEH were included in the study group and were compared with those diagnosed with atrophic endometrium (AE). Outcome data were obtained until February 2018. The main outcomes were risk of progression to endometrial carcinoma and risk of persistence, recurrence or new development of endometrial hyperplasia (EH) (‘persistent EH’). Logistic regression analysis was used to identify covariates that were independent risk factors for progression to endometrial cancer or persistent EH.Results: During the study period, 1808 women aged 55 or older underwent endometrial sampling. The median surveillance time was 10.0 years. Seventy‐two women were found to have a current or recent diagnosis of NEH and were compared with 722 women with AE. When compared to women with AE, women with NEH had significantly higher body mass index (33.9 kg/m2 vs 30.6 kg/m2; P = 0.01), greater endometrial thickness (10.00 mm vs 6.00 mm; P = 0.01) and higher rates of progression to type‐1 endometrial cancer (8.3% vs 0.8%; P = 0.0003) and persistent NEH (22.2% vs 0.7%; P < 0.0001). They also had a higher rate of progression to any type of uterine cancer or persistent EH (33.3% vs 3.5%; P < 0.0001). Women with NEH had a significantly higher rate of future surgical intervention (51.4% vs 15.8%; P < 0.0001), including future hysterectomy (34.7% vs 9.8%; P < 0.0001). On multivariable logistic regression analysis, only NEH remained a significant risk factor for progression to endometrial cancer or persistence of EH.Conclusions: Postmenopausal women with NEH are at significant risk for persistent EH and progression to endometrial cancer, at rates higher than those reported previously. Guidelines for the appropriate management of postmenopausal women with NEH are needed in order to decrease the rate of persistent disease or progression to cancer. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.